HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Supplement Firm Touts COVID-19 Study, Kicks Off Promotional Campaign With Tae Bo Creator

Executive Summary

Todos Medical, warned in 2021 about COVID-19 claims, could prompt a second warning about linking Tollovid  to the coronavirus with recent announcement of test results. Firm also has appointed VPs of marketing and of government affairs since FTC in April 2021 warned about claims on its website, its social media pages and in a store.

You may also be interested in...



US FTC Diagnoses Omicron Symptom: More Fraudulent COVID-19 Treatment Claims

Agency says emergence of Omicron variant spurred marketers of products and services from peptide therapy to herbal remedies, and from nasal irrigation to intravenous drips to make false COVID-19 claims. 

Urged By US FDA To Boost Infant Formula Supply, Additional Providers Still Must Wait For Approval

Patricia Hansen, CFSAN’s Office of Nutrition and Food Labeling deputy director and John Verbeten, deputy director for Import Operations Enforcement laid out the FDA's new enforcement guidance, and urged businesses with available formula to wait for approval before distributing formula in the US.

House Appropriators Sound Off During FDA Hearing About Formula, More Consumer Health Issues

Before Agriculture/FDA subcommittee about FY2023 budget, Commissioner Robert Califf says FDA needs more resources to address unlisted fragrances in menstrual products and doesn’t have good regulatory options for hemp and kratom. His formula emergency comments leave members frustrated.

Topics

UsernamePublicRestriction

Register

RS152392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel